<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00656812</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_MALT</org_study_id>
    <secondary_id>EudraCT 2008-000767-41</secondary_id>
    <nct_id>NCT00656812</nct_id>
  </id_info>
  <brief_title>Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma</brief_title>
  <official_title>Phase II Trial of Rituximab Plus 2CdA in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lipomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate whether a Rituximab plus 2 CdA combination therapy&#xD;
      is effective and safe in the treatment of patients with advanced or relapsed lymphoma of the&#xD;
      mucosa associated lymphoid tissue (MALT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, there is no chemotherapeutic standard treatment for patients with MALT lymphoma&#xD;
      either presenting with disseminated disease or with relapsing/refractory disease following&#xD;
      local treatment (including radiation) or eradication of HP. Various compounds have been&#xD;
      tested, including alkylating agents such as cyclophosphamide or chlorambucil, the nucleoside&#xD;
      analog cladribine (2CdA), as well as combination regimens including CHOP or MCP&#xD;
      (mitoxantrone, chlorambucil, prednisone), but only limited data exists from prospective&#xD;
      trials. Thus, trials to evaluate the potential of new compounds in patients with advanced&#xD;
      MALT lymphoma are not only justified, but seem warranted.&#xD;
&#xD;
      While systemic approaches were until recently thought to be justified only in patients with&#xD;
      disseminated disease, emerging data suggest that also patients with localized disease&#xD;
      potentially amenable to radiation may benefit from systemic treatment. This has been&#xD;
      demonstrated for ocular adnexal MALT lymphoma and recently also for gastric MALT lymphoma in&#xD;
      a randomized fashion, where application of chemotherapy resulted in a significantly longer&#xD;
      time to relapse as opposed to surgery or radiation without impairing overall survival.&#xD;
&#xD;
      Both 2CdA and rituximab have been demonstrated as active single agents in MALT lymphoma with&#xD;
      mild toxicity profiles and no data on combination therapy with rituximab plus chemotherapy in&#xD;
      MALT lymphoma have been published to date. This study will therefore evaluate the efficacy&#xD;
      and safety of Rituximab plus 2CdA in patients with advanced or relapsed lymphoma of the&#xD;
      mucose associated lymphoid tissue.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>After 2, 4 and 6 cycles of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival and relapse-free survival</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lymphoma of Mucosa-Associated Lymphoid Tissue</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy Rituximab plus 2CdA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 on day 1 of a 21-day treatment cycle</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2-CdA</intervention_name>
    <description>0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Litak</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven diagnosis of MALT lymphoma of any localization&#xD;
&#xD;
          -  Disseminated disease upon diagnosis in case of gastric lymphoma or first or greater&#xD;
             relapse after local therapy (including gastrectomy or surgery), prior chemotherapy or&#xD;
             HP-eradication. In addition, also patients with localized gastric lymphoma judged&#xD;
             refractory to HP-eradication by a minimum follow-up of 12 months after successful&#xD;
             HP-eradication can be included in the study.&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  ECOG performance status of 0,1 or 2&#xD;
&#xD;
          -  Age at least 18 years&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Adequate cardiac, renal and liver function tests (LVEF &gt; 50%, serum creatinine &lt; 2.5&#xD;
             mg/dl, ALAT or ASAT &lt; 2.5 x upper limit of normal range (ULN), alkaline phosphatase &lt;&#xD;
             2.5 x ULN, serum bilirubin &lt; 2.0 mg/dl)&#xD;
&#xD;
          -  Patient must be willing and able to comply with the protocol for the entire study&#xD;
             duration&#xD;
&#xD;
          -  Women of child-bearing potential must have a negative pregnancy test and must agree to&#xD;
             use effective contraception for the entire treatment period&#xD;
&#xD;
          -  Patient's written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lymphoma histology other than MALT lymphoma or MALT lymphoma transforming to diffuse&#xD;
             large cell lymphoma (&quot;high grade lymphoma&quot;)&#xD;
&#xD;
          -  Use of any investigational agent 30 days prior to inclusion&#xD;
&#xD;
          -  History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the&#xD;
             skin or carcinoma in situ of the cervix within the last 5 years&#xD;
&#xD;
          -  Major surgery, other than diagnostic surgery, within the last 4 weeks&#xD;
&#xD;
          -  Evidence of CNS involvement&#xD;
&#xD;
          -  A history of uncontrolled seizures, central nervous system disorders or psychiatric&#xD;
             disability judged by the investigator to be clinically significant and adversely&#xD;
             affecting compliance to study drugs&#xD;
&#xD;
          -  Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic&#xD;
             coronary artery disease and cardiac arrhythmias not well controlled with medication)&#xD;
             or myocardial infarction within the last 6 months&#xD;
&#xD;
          -  Inadequate hematological status at baseline prior to study entry: Dependency on red&#xD;
             blood cell and/or platelet transfusions, ANC (absolute neutrophile count (segmented +&#xD;
             bands) &lt;1.0 x 109/L&#xD;
&#xD;
          -  Patients with active opportunistic infections&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Raderer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AKH Wien / Universitaetsklinik fuer Innere Medizin I</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Innsbruck/ Klinik für Innere Medizin</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Stadt Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik f. Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Wien / Universitaetsklinik fuer Innere Medizin I</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>April 2, 2008</study_first_submitted>
  <study_first_submitted_qc>April 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2008</study_first_posted>
  <last_update_submitted>December 23, 2013</last_update_submitted>
  <last_update_submitted_qc>December 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Richard Greil</name_title>
    <organization>Arbeitsgemeinschaft medikamentoese Tumortherapie</organization>
  </responsible_party>
  <keyword>advanced MALT lymphoma</keyword>
  <keyword>Rituximab</keyword>
  <keyword>2CdA</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

